- 1 Association between Use of Qingfei Paidu Tang and Mortality in
- **Hospitalized Patients with COVID-19: A national retrospective**
- 3 registry study

- Lihua Zhang¹* PhD, Xin Zheng¹* PhD, Xueke Bai¹ MS, Qing Wang¹ MS, Bowang
- 6 Chen¹ PhD, Haibo Wang² MPH, Jiapeng Lu¹ PhD, Shuang Hu¹ PhD, Xiaoyan Zhang¹
- MS, Haibo Zhang¹ MD, Jiamin Liu¹ MD, Ying Shi³ BMS, Zhiye Zhou³ MS, Lanxia
- 8 Gan³ BE, Xi Li^{1,4}¶PhD, Jing Li^{1,4,5}¶PhD
- ¹ National Clinical Research Center for Cardiovascular Diseases, State Key
- Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for
- 12 Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union
- 13 Medical College, Beijing, People's Republic of China
- ²Clinical Trial Unit, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou
- 15 Province, People's Republic of China
- ³ China Standard Medical Information Research Center, Shenzhen, People's Republic
- 17 of China
- ⁴ Central China Subcenter of the National Center for Cardiovascular Diseases,
- 19 Zhengzhou, People's Republic of China
- ⁵ Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, People's
- 21 Republic of China.
- 22 *Joint first authors

23 ¶ Joint correspondence authors Correspondence: 24 25 Jing Li, National Clinical Research Center for Cardiovascular Diseases, State Key 26 Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for 27 Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 28 Medical College, Beijing, China. Electronic address: jing.li@fwoxford.org. 29 30 Xi Li, National Clinical Research Center for Cardiovascular Diseases, State Key 31 Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for 32 Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 33 Medical College, Beijing, China. Electronic address: xi.li@fwoxford.org. 34 35 36 Word count: 2911 (not including the abstract, references, tables, boxes, or figure 37 legends). **Number of tables and figures:** 2 tables and 3 figures are included in this article. 38 39

ABSTRACT

40

61

41 **Background** Qingfei Paidu Tang (QPT), a formula of traditional Chinese medicine, which was 42 43 suggested to be able to ease symptoms in patients with Coronavirus Disease 2019 (COVID-19), has been recommended by clinical guidelines and widely used to treat 44 45 COVID-19 in China. However, whether it decreases mortality remains unknown. **Purpose** 46 47 We aimed to explore the association between QPT use and in-hospital mortality 48 among patients hospitalized for COVID-19. 49 Study design 50 A retrospective study based on a real-world database was conducted. 51 Methods 52 We identified patients consecutively hospitalized with COVID-19 in 15 hospitals 53 from a national retrospective registry in China, from January through May 2020. 54 Data on patients' characteristics, treatments, and outcomes were extracted from the 55 electronic medical records. The association of QPT use with mortality was evaluated 56 using Cox proportional hazards models based on propensity score analysis. **Results** 57 58 Of the 8939 patients included, 28.7% received QPT. The crude mortality was 1.2% 59 (95% confidence interval [CI] 0.8% to 1.7%) among the patients receiving QPT and 4.8% (95% CI 4.3% to 5.3%) among those not receiving QPT. After adjustment for 60

patient characteristics and concomitant treatments, QPT use was associated with a

- relative reduction of 50% in in-hospital mortality (hazard ratio, 0.50; 95% CI, 0.37 to
- 63 0.66 P <0.001). This association was consistent across subgroups by sex and age.
- Meanwhile, the incidence of acute liver injury (8.9% [95% CI, 7.8% to 10.1%]vs.
- 65 9.9% [95% CI, 9.2% to 10.7%]; odds ratio, 0.96 [95% CI, 0.81% to 1.14%], P
- 66 =0.658) and acute kidney injury (1.6% [95% CI, 1.2% to 2.2%] vs. 3.0% [95% CI,
- 67 2.6% to 3.5%]; odds ratio, 0.85 [95% CI, 0.62 to 1.17], P = 0.318) was comparable
- between patients receiving QPT and those not receiving QPT. The major study
- 69 limitations included that the study was an observational study based on real-world
- data rather than a randomized control trial, and the quality of data could be affected
- by the accuracy and completeness of medical records.
- 72 **Conclusions**
- 73 QPT was associated with a substantially lower risk of in-hospital mortality, without
- 74 extra risk of acute liver injury or acute kidney injury among patients hospitalized with
- 75 COVID-19.
- 76 **Key words** Qingfei Paidu Tang; Mortality; COVID-19
- 77 **Abbreviations**
- 78 QPT: Qingfei Paidu Tang
- 79 COVID-19: Coronavirus Disease 2019
- 80 **IQR**: interquartile range
- 81 SMD: standard mean difference
- 82 IPTW: inverse probability treatment weighting
- 83 HR: hazard ratios

84 OR: odds ratios

86

87

85 CI: confidence interval

Introduction

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Coronavirus Disease 2019 (COVID-19), caused by a novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has posed a huge threat to global health as the largest pandemic in a century. Nearly 50 million people worldwide have been infected, of whom over 1.2 million died by middle November2020. The pandemic is still evolving, effective treatments against COVID-19 are therefore urgently needed to reduce the mortality of COVID-19. Qingfei Paidu Tang (QPT), a traditional Chinese medicine, was formulated on the basis of one of the classics of traditional Chinese medicine, Treatise on Febrile and Miscellaneous Diseases (Shang Han Zabing Lun).² It is a compound prescription containing four traditional Chinese medicine prescriptions, each of which has been widely applied as therapy of common cold, fever, influenza, and other virus infection.³⁻⁷ Basic research also found that QPT possessed properties such as antivirus, ^{8,9} anti-inflammation, ⁸⁻¹³ and immune regulation, ^{8,11-13} which might be beneficial for patients with COVID-19. Moreover, several small observational studies in China have suggested its potential effectiveness in relieving symptom (i.e., fever and cough) and preventing disease progression in patients with COVID-19. 14-17 Therefore, OPT has been recommended in the Chinese guidelines for the treatment of Coronavirus Disease 2019 (COVID-19) since early February 2020 and widely used in China. 18 However, it is unknown whether it could reduce the mortality of COVID-19. Accordingly, using the data from a national retrospective registry, we sought to evaluate the effectiveness and safety of QPT in COVID-19. Specifically, we

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

hypothesized that QPT use would be associated with a lower risk of in-hospital mortality in patients with COVID-19, and tested it using propensity score analysis. We also assessed whether there was an association of QPT with the incidence of acute liver injury and acute renal injury during hospitalization. Methods **Data Sources** In a government-mandated national registry, hospitalizations for COVID-19 in all the designated hospitals across China were registered retrospectively. Information relating to patient characteristics, treatments, and outcomes, in the electronic medical records (EMR), were required to be submitted to a system deployed by the National Health Commission of China, in forms of either structured database for the front page, or unstructured text for the progress notes, lab test results, and physician's orders. By the date of May 6th 2020, over 40 thousand COVID-19 cases from more than five hundred hospitals have been included. **Ethical approval** The Ethics Committee at the National Center for Cardiovascular Diseases (NCCD)/Fuwai Hospital ethics committee approved this study and the Ethics Committee at the First Affiliated Hospital, Sun Yat-sen University approved the current analysis. Informed consent of individual patients was waived.

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

Study cohort Among all the designated hospitals providing inpatient care for COVID-19 in the national registry, we excluded hospitals that were ineligible for data extraction or analysis for the following two reasons. First, the number of patients hospitalized with COVID-19 was less than 100. Second, the number of patients receiving QPT in the hospitals was less than 50. In the end, 15 hospitals were included in our study, all of which were located in Hubei province. Among eligible hospitals, we included all patients aged ≥18 years discharged between January and May, 2020 with a confirmed diagnosis of COVID-19. We identified these patients, according to International Classification of Diseases, Clinical Modification codes revision 10 (U07.100, U07.100.00x, U07.100.00x001, U07.100.00x002, U07.100.00x003), when available, or through principal diagnosis terms noted at discharge. We excluded patients who were transferred out, since the records of their hospitalizations were truncated. Patients who died or were discharged within 24 hours of admission were also excluded from the analysis, because the testing and treatments for them were likely to be influenced due to the short length of hospital stay. **Data Extraction** For each patient, the demographic characteristics (age and sex), prior medical histories/comorbidities (hypertension, diabetes, coronary heart disease, stroke, chronic kidney diseases, chronic obstructive pulmonary disease, and cancer), clinical status at admission (critical or not), and in-hospital death was obtained from the front-page

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

database or progress notes. The vital signs (heart rate, blood pressure, and respiratory rate) at admission were extracted from the progress notes. The in-hospital medications (QPT, Arbidol, Ribavirin, Oseltamivir, Ganciclovir, Lopinavir, Lianhuaqingwen, Xuebijing, Diammonium Glycyrrhizinate, Methylprednisolone, Dexamethasone, and Interferon) were extracted from the physician orders, progress notes, and nurse records. The in-hospital acute liver injury and acute kidney injury were identified based on the front-page database, progress notes, and lab test results. We searched predefined keywords in unstructured text of the submitted medical records using Python software (version 3.6) and MYSQL software (version 8.0), in order to extract the data. Particularly, research clinicians randomly selected and reviewed 5% of the medical records in the hospitals with QPT use rate under 20%, to ensure the exhaustion of synonyms of this medication and completeness of data extraction. Furthermore, to ensure the data accuracy, research clinicians adjudicated the prior medical history/comorbidities based on the progress note. Treatment and outcome measures As the treatment of interest in our analysis, QPT use was defined as receiving this medication for no less than three days during the hospitalization, according to the Chinese diagnosis and treatment protocol for COVID-19 (Trial Version 6) (i.e., one formula a day, three formulas were defined as a course of treatment). 18 Correspondently, the study cohort was categorized into two treatment groups – patients receiving QPT and those not receiving QPT. Meanwhile, we also explored the effectiveness and safety of QPT between patients who ever received QPT during

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

hospitalization and those who did not. The outcome measure of effectiveness was in-hospital mortality. The outcome measure of safety included acute liver injury and acute kidney injury during hospitalization. Acute liver injury was defined as documented acute liver injury, acute liver renal insufficiency, acute liver failure, hepatic encephalopathy, or hepatic coma, then adjudicated based on the elevation in aspartate aminotransferase, alanine aminotransferase, or total bilirubin. Acute renal injury was defined as documented acute renal failure, acute renal injury, or acute renal insufficiency, then adjudicated based on the elevation in serum creatinine. Statistical analysis We described participant characteristics, treatments, and outcomes, with frequencies and percentages for categorical variables, while means ± standard deviations or median with interquartile range (IQR) for continuous variables. The difference between groups was estimated by standard mean difference (SMD), and absolute values less than 0.1 was considered small differences. 19 We conducted a statistical power analysis in advance, based on the projected sample size of this retrospective registry. Assuming the in-hospital mortality rate was 4% in patients not receiving QPT, a total sample size of 9000 can achieve a statistical power of 80% at a 2-sided 0.05 significance level to detect a hazard ratio of 0.7 or below, for the treatment with a 30% or greater prevalence. We used inverse probability treatment weighting (IPTW) based on probability of receiving treatment to make the characteristics between the two treatment groups

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

comparable. The probability of receiving QPT was estimated by multilevel logistic regression that adjusted for baseline characteristics including demographics, comorbidities, and prior histories extracted in previous referred (Table S1), with hospital as random effect. To assess the effectiveness of QPT, we obtained hazard ratios (HR) between treatment groups with developing frailty proportional hazards models on in-hospital death, accounted hospital as random effect, adjusted for other in-hospital medications, and weighted with inverse probability of QPT use. We then plotted Kaplan-Meier curve in patients receiving and those not receiving QPT. To assess the safety of QPT, we obtained odds ratios (OR) with the multilevel logistic regression on acute liver injury and acute renal injury, which handled random effect, adjustment, and weight, using the similar approaches described earlier. We also added interaction items to explore the heterogeneity of effectiveness across subgroups by age ($<60, 60-69, or \ge$ 70 years), sex (male or female), and prior medical history/comorbidities (with any or without). In each subgroup, we recalculated inverse probability and reweighting separately, as aforementioned. We conducted two sensitivity analysis. First, we matched propensity score between patients receiving and not receiving QPT using the nearest-neighbour method, to create two groups with similar characteristics and sample size. Second, we added the propensity score as covariate in the frailty model without weighting, to account for the difference between treatment groups. In the submitted medical records, small proportions of blood pressure (1.7%),

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

heart rate (0.1%), and respiratory rate (0.2%) were missing. Assuming that these data were missing at random, we applied a multiple imputation method based on Markov Chain Monte Carlo by PROC MI procedure in SAS to impute missing value.²⁰ Two-tailed P values were reported with P<0.05 considered to indicate statistical significance. All statistical analyses were performed with SAS software, version 9.4 (SAS Institute, Cary, NC). Results **Study Participants** There were 9115 patients with COVID-19 admitted to the 15 designated hospitals in this study, with the numbers of cases in each included hospital ranging from 140 to 1856. After excluding 96 patients with age <18 years, 66 patients transferred out, and 14 patients with the length of stay less than 24 hours, 8939 eligible cases were included in the analysis (Figure 1). Of them, the average age was 55.9 ± 15.6 years, and 53.4% (4771) were women. 4.4% (390) patients were at critical state at admission, while 33.7% (3016) had hypertension, and 15.2% (1357) had diabetes. Of these patients, 2833 (31.7%) ever received QPT during hospitalization, with a median treatment duration of 6 (4 to 9) days. Half of the QPT users received the first formula within 5 days after hospitalization. The timing of QPT use after hospitalization was shown in Figure S1. In the study cohort, 2568 patients (28.7%) received QPT for no less than 3 days and 6371 (71.3%) did not. The patient characteristics of the two treatment groups

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

were provided in Table 1. Unweighted comparisons showed that patients who received QPT were younger (SMD>0.1). After adjustment for inverse probability of treatment weighting, all covariates were well balanced (i.e., standardized mean differences were <0.1). The distributions of inverse probability score weights of treatment groups were shown separately in Figure S2. **Outcomes** During hospitalization with a median length of stay of 15 (9 to 21) days, 334 (3.7%) patients died. The crude mortality was 1.2% (95% confidence interval [CI], 0.8% to 1.7%) among patients who received QPT and 4.8% (95% CI, 4.3% to 5.3%) among patients who did not (Figure 2). In the unadjusted analysis, patients who received QPT were less likely to die than patients who did not receive QPT (hazard ratio, 0.17; 95% CI, 0.11% to 0.26%, P<0.001). In the Cox model with inverse propensity score weighting, all covariates in the Cox model were shown in Table S2. QPT use was associated with a lower mortality risk (adjusted hazard ratio, 0.50; 95% CI, 0.37 to 0.66, *P*<0.001). In terms of sex and age, no significant differences were observed among their subgroups in the associations between QPT treatment and in-hospital mortality (all P for interaction>0.05). Although significant heterogeneity in associations between QPT treatment and in-hospital mortality were detected between subgroups by prior medical history/comorbidities status (P for interaction=0.020), the significantly lower mortality risk for patient receiving QPT was observed in both these subgroups (Figure 3).

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

Regarding the safety of QPT, patients who received QPT had a comparable incidence of acute hepatic injury (crude rate, 8.9% [95% CI, 7.8% to 10.1%] vs 9.9% [95% CI, 9.2% to 10.7%]; adjusted OR, 0.96 [95% CI, 0.81 to 1.14], P = 0.658) and acute kidney injury (crude rate, 1.6% [95% CI, 1.2% to 2.2%] vs. 3.0% [95% CI, 2.6% to 3.5%]; adjusted OR, 0.85 [95% CI, 0.62 to 1.17], P = 0.318), in comparison with those who did not. Furthermore, we also conducted the analysis of the effectiveness and safety of QPT between patients who ever received QPT during hospitalization and those who did not, and found similar results with those mentioned above (Table S3-4). **Sensitivity Analyses** In addition to the IPTW analysis, we matched 3492 patients based on their propensity score (1746 patients receiving QPT and 1746 patients not receiving QPT). The two groups were well-balanced in characteristics and concomitant treatments (Table S5, Figure S3). The risk of mortality in patients who received QPT was significantly lower than in those who did not receive QPT (1.1% [95% CI, 0.7% to 1.7%] vs 2.7% [95% CI, 2.0% to 3.6%], HR, 0.42; 95% CI, 0.24 to 0.74; P= 0.002) (Table 2 and Figure S4). In the meantime, patients receiving QPT had a comparable incidence of acute kidney injury (1.1% [95% CI, 0.7% to 1.8%] vs. 1.9% [95% CI, 1.3% to 2.6%]; OR, 0.74 [95% CI, 0.40 to 1.35], P = 0.327) compared with the patients who did not, but a lower risk of acute liver injury (5.4% [95% CI, 4.4% to 6.5%] vs. 8.1% [95% CI, 6.9% to 9.5%]; OR, 0.72 [95% CI, 0.54 to 0.96], P =0.025). We also included the propensity score as an additional covariate in the models, in

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

which patients who received QPT had a significantly lower risk of mortality than those who did not receive QPT (adjusted HR, 0.24 95% CI, 0.15 to 0.37; P<0.001). Meanwhile, patients receiving QPT had comparable incidence of acute liver injury (OR, 0.93 [95% CI, 0.76 to 1.14], P = 0.497) and acute kidney injury (OR, 0.74 [95% CI, 0.50 to 1.10], P = 0.133) compared with the patients not receiving QPT. **DISCUSSION** In this analysis based on a national registry of hospitalized patients with COVID-19, we first demonstrated that QPT use was associated with halving the risk of in-hospital mortality, without significant increase in risk of adverse effects, such as acute liver injury or acute kidney injury. Our findings have provided new evidence and insights regarding the treatment of COVID-19. Our study has extended the literature on the effectiveness of QPT for patients with COVID-19. First, this is the first study assessing the association between the QPT use and in-hospital mortality that is considered the most important and objective outcome metrics, rather than surrogate indicators widely used before. Second, in comparison with prior studies in China about QPT for COVID-19 treatment, 14-17 our study has involved an over ninety-time larger sample size that ensured sufficient statistical power even for subgroup analysis. Third, using various propensity score approaches, we established control groups to enable appropriate comparisons in both effectiveness and safety of QPT. Forth, this national registry included consecutive patients from multiple Chinese hospitals, which represented the use and effectiveness

of QPT in real-world practice.

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

The effects of QPT on decreasing mortality of COVID-19 observed in our study are supported by the mechanisms shown in prior experimental studies, which included antivirus, ^{8,9} anti-inflammation, ⁸⁻¹³ immune regulation, ^{8,11-13} regulating metabolism, ^{9,12} anti-platelet aggregation, ¹⁰ and organ protection. ^{11,13} QPT was composed of four traditional Chinese medicine prescriptions, which were shown to be separately effective in antivirus, 3,5 anti-inflammatory, or immuno-modulating. QPT has multiple components acting on the multiple pathways. Some studies employed molecular network and network pharmacology to analyse the ingredients of QPT, and found that the key active ingredients, including quercetin, luteolin, kaempferol, naringenin, and isorhamnetin, could alleviate excessive immune responses, by regulating the function of cytokines related pathways, such as tumour necrosis factor signalling pathways and mitogen-activated protein kinases signalling pathways. 11-13 Further research is needed to fully investigate the underlying mechanism of the effect of QPT. In this study, we did not observe the elevated risk of acute liver injury or acute kidney injury among patients receiving QPT. This is consistent with the previous observational studies. 14-17 Moreover, our findings are particularly reassuring given the complexity in comorbidities (such as hypertension, diabetes and chronic kidney disease) and concomitant treatments (such as antivirals, corticosteroids and immunomodulators) observed in our cohort. Nevertheless, long-term safety related to QPT still needs to be verified in future studies.

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

This study has provided valuable evidence and prospects for the treatment of COVID-19. Currently, there are globally nearly 7.5 million active cases that need treatments. However, there is no evidence about any medication that could decrease mortality in COVID-19 except for dexamethasone, which has been proved to be able to reduce the 28-day mortality in those who received mechanical ventilation or oxygen alone. 21,22 To the best of our knowledge, this is the first study implying that QPT could reduce the mortality risk of patients with COVID-19. Our findings were consistent across subgroups, and robust regardless of analytic methods. It is encouraging that the use of QPT can probably prevent tens of thousands of deaths, if our findings are further confirmed and applied globally. Limitations The results of our study should be interpreted in the context of several limitations. First, due to the nature of observational study, we cannot exclude the influence of residual confounders. However, after the IPTW, patients who received QPT had higher rates of co-morbidities which was positively related to mortality risk, compared with those who did not received QPT. Thus, the effectiveness we observed tended to be conservative. Second, our study was based on real-world data and the quality of data could be affected by the accuracy and completeness of medical records. Therefore, we only included the highly reliable variables on patient characteristics, treatments, and outcomes in the analysis. Third, our study merely collected in-hospital outcomes, therefore, we could not evaluate the long-term effectiveness and safety. Finally, all the patients in our study were from China, and the beneficial effects of

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

QPT in other racially diverse populations still await further validation. Conclusion Among the patients hospitalized for COVID-19, the use of QPT was associated with halving the risk of mortality, without raising the risk of acute liver injury or acute kidney injury. Further validation with randomized controlled trials is needed to support the use of QPT worldwide for COVID-19. **Declarations Ethics approval** The Ethics Committee at the First Affiliated Hospital, Sun Yat-sen University approved the current analysis. Informed consent of individual patients was waived. **Consent for publication** Not applicable Availability of data and materials The data sharing needs to be approved by national registry, which is under the supervision of National Health commission. However, on site data audit is allowed under current regulation. **Competing interests** Dr Li reported receiving research grants, through Fuwai Hospital, from the People's Republic of China for work to improve the management of hypertension and blood lipids

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

and to improve care quality and patient outcomes of cardiovascular disease; receiving research agreements, through the National Center for Cardiovascular Diseases and Fuwai Hospital, from Amgen for a multicenter clinical trial assessing the efficacy and safety of omecamtiv mecarbil and for dyslipidemic patient registration; receiving a research agreement, through Fuwai Hospital, from Sanofi for a multicenter clinical trial on the effects of sotagliflozin; receiving a research agreement, through Fuwai Hospital, with the University of Oxford for a multicenter clinical trial of empagliflozin; receiving a research agreement, through the National Center for Cardiovascular Diseases, from AstraZeneca for clinical research methods training outside the submitted work; and receiving a research agreement, through the National Center for Cardiovascular Diseases, from Lilly for physician training outside the submitted work. No other disclosures were reported. **Funding** This project was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Science (2020-I2M-Cov19-003) and the National Natural Science Foundation of China under Grants (No. U1611261). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. **Authors' contributions** JL and XL conceived of the project and take responsibility for all aspects of it. JL and XL designed the study. LHZ and XZ wrote the first draft of the manuscript, with further contributions from JPL, XKB, HBZ, JML, BWC, QW, XYZ, HS, HBW, YS, ZYZ and LXG. XKB and SH did the statistical analysis. YZW, ZYZ, ESS, WQ, BWC, YS and XYZ collected, extracted, processed, and cleaned the data. All authors

have read and approved the submission of this review, which neither has been published on any other peer-review platforms, nor is being considered for publication elsewhere, in whole or in part, in any language. Acknowledgements We appreciate the Bureau of Medical Administration and Medical Service Supervision, National Health Commission of China, for the approval and support on collecting data. We appreciate all the COVID-19 designated hospitals for submitting medical records, and China Standard Medical Information Research Center for the support in collecting and processing data. We appreciate the team in National Center for Cardiovascular Diseases for their multiple contributions in data cleaning and manuscript coordinating.

REFERENCES

- 1. World Health Organization. Coronavirus disease (COVID-19) pandemic.
- 417 https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed Nov 15 2020
- 418 2. National Administration of Traditional Chinese Medicine.
- 419 http://www.satcm.gov.cn/hudongjiaoliu/guanfangweixin/2020-03-05/13622.html. Accessed Sep 22
- 420 2020

- 421 3. Shi KY, Han GX, Zhang WW, et al. Systematic Evaluation of Xiaochaihu Decoction Combined
- 422 with Antiviral Agent in the Treatment of Chronic Hepatitis B. Evaluation and Analysis of Drug-Use
- 423 in Hospitals of China. 2019; 19: 1039-1050.
- 424 4. Zheng CS, Wu YS, Bao HJ, et al. Understanding the polypharmacological anticancer effects of
- 425 Xiao Chai Hu Tang via a computational pharmacological model. Exp Ther Med. 2014; 7: 1777-1783...
- 426 5. Hsieh CF, Lo CW, Liu CH, et al. Mechanism by which ma-xing-shi-gan-tang inhibits the entry
- of influenza virus. J Ethnopharmacol. 2012;143:57-67.
- 428 6. Lin CC, Wang YY, Chen SM, et al. Shegan-Mahuang Decoction ameliorates asthmatic airway
- 429 hyperresponsiveness by downregulating Th2/Th17 cells but upregulating CD4+FoxP3+ Tregs. J
- 430 Ethnopharmacol. 2020; 253: 112656.
- 431 7. Yang Y, Zhang DM, Liu JH, et al. Wuling San protects kidney dysfunction by inhibiting renal
- 432 TLR4/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced
- 433 hyperuricemic mice. J Ethnopharmacol 2015; 169: 49-59.
- 434 8. Zhao J, Tian SS, Yang J, et al. Investigating the mechanism of Qing-Fei-Pai-Du-Tang for the
- 435 treatment of Novel Coronavirus Pneumonia by network pharmacology. Chinese Traditional and
- 436 Herbal Drugs 2020; 51: 829-835.
- 9. Chen J, Wang Y-k, Gao Y, et al. Protection against COVID-19 injury by qingfei paidu decoction
- via anti-viral, anti-inflammatory activity and metabolic programming.
- 439 Biomed Pharmacother 2020; 129: 110281.
- 440 10. Yang R, Liu H, Bai C, et al. Chemical composition and pharmacological mechanism of Qingfei
- Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In
- silico and experimental study. *Pharmacol Res* 2020; 157: 104820.
- 443 11. Xu DY, Xu YL, Wang ZW, et al. Mechanism of Qingfei Paidu decoction on COVID-19 based
- on network pharmacology. *Pharmacol Clin Chin Materia Med* 2020; 36: 26-31.
- 445 12. Xu TF, He CG, Yang K. Network pharmacology-based study on material basis and mechanism
- 446 of Qingfei Paidu Decoction against Novel coronavirus pneumonia. . Natural Product Research and
- 447 Development 2020, http://kns.cnki.net/kcms/detail/51.1335.Q.20200413.1918.018.html. Accessed
- 448 Sep 2 2020
- 449 13. Wu H, Wang JQ, Yang YW, et al. Preliminary exploration of the mechanism of Qingfei Paidu
- 450 decoction against novel coronavirus pneumonia based on network pharmacology and molecular
- docking technology. *Acta Pharmaceutica Sinica* 2020; 55: 374–383.
- 452 14. Wang R, Yang SJ, Xie C, et al. Clinical efficacy of Qingfei Paidu Decoction in the treatment of
- 453 COVID-19. Pharmacology and Clinics of Chinese Materia Medica 2020; 36: 13-18.
- 454 15. Zhang LJ, Fan H, Chen R, et al. Rational usage of Oingfei Paidu Decoction from clinical
- practice. Journal of Traditional Chinese Medicine 2020. Available from:
- 456 http://kns.cnki.net/kcms/detail/11.2166.R.20200326.1355.002.html. Accessed Sep 2 2020
- 457 16. Li KY, An W, Xia F, et al. Observation on clinical effect of modified Qingfei Paidu Decoction in

- treatment of COVID-19. Chinese Traditional and Herbal Drugs 2020; **51**: 2046-9.
- 459 17. Xin SY, Cheng XQ, Zhu B, et al. Clinical retrospective study on the efficacy of Qingfei Paidu
- decoction combined with Western medicine for COVID-19 treatment. Biomed Pharmacother 2020;
- 461 129: 110500.

476

- 462 18. National Health Commission of the People's Republic of China. Diagnosis and Treatment
- Protocol for COVID-19 (Trial Version 6.0). 2020. Available from:
- 464 http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1b
- 465 <u>c54639af227f922bf6b817.pdf</u>. Accessed Sep 02 2020.
- 466 19. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment
- weighting (IPTW) using the propensity score to estimate causal treatment effects in observational
- 468 studies. Stat Med 2015; 34:3661-3679.
- 20. Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological
- 470 and clinical research: potential and pitfalls. BMJ (Clinical research ed) 2009; 338: b2393-b.
- 471 21. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19
- 472 Preliminary Report. N Engl J Med. 2020. doi: 10.1056/NEJMoa2021436.
- 473 22. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and
- 474 Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020. 324:782-793.

Table 1. Baseline characteristics of patients by Qingfei Paidu Tang use

	No QPT	QPT	SMD before IPTW	SMD after IPTW
	N=6371	N=2568		
Demographic				
Women	3401 (53.4)	1370 (53.3)	-0.0007	0.0115
Age, years			0.1081	0.0263
< 60	3626 (56.9)	1594 (62.1)		
60-70	1511 (23.7)	555 (21.6)		
> 70	1234 (19.4)	419 (16.3)		
Prior history/Comorbidities				
Hypertension	2191 (34.4%)	825 (32.1%)	-0.0481	0.0175
Diabetes	1014 (15.9%)	343 (13.4%)	-0.0724	0.0130
Coronary heart disease	475 (7.5%)	211 (8.2%)	0.0283	0.0284
Stroke	469 (7.4%)	140 (5.5%)	-0.0781	0.0602
Chronic kidney disease	159 (2.5%)	57 (2.2%)	-0.0182	0.0265
COPD	116 (1.8%)	41 (1.6%)	-0.0173	0.0312
Cancer	201 (3.2%)	84 (3.3%)	0.0066	0.0190
Clinical characteristics at admission				
SBP, median (IQR), mmHg	130(120, 140)	128(120, 140)	-0.0308	0.0466
DBP, median (IQR), mmHg	80(74, 89)	80(74, 88)	0.0256	0.0316
HR, median (IQR), breaths per min	84(78, 95)	84(78, 96)	0.0077	0.0340
RR >24 breaths per min	592 (9.3%)	195 (7.6%)	-0.0611	0.0713
Critical state at admission	274 (4.3%)	116 (4.5%)	0.0105	-0.0019
Medication				
Antiviral				
Arbidol	3447 (54.1%)	1969 (76.7%)	0.4884	0.2971
Ribavirin	1150 (18.1%)	585 (22.8%)	0.1175	-0.0707
Oseltamivir	1347 (21.1%)	666 (25.9%)	0.1131	-0.0627
Ganciclovir	323 (5.1%)	183 (7.1%)	0.0860	-0.1166
Lopinavir/Ritonavir	777 (12.2%)	371 (14.4%)	0.0663	-0.0494
Traditional Chinese medicine				
Lianhua Qingwen	3172 (49.8%)	1563 (60.9%)	0.2242	0.1008
Xuebijing	624 (9.8%)	503 (19.6%)	0.2793	0.0284
Diammonium glycyrrhetate	996 (15.6%)	315 (12.3%)	-0.0973	0.0253

	No QPT	QPT	SMD before IPTW	SMD after IPTW
	N=6371	N=2568		
Corticosteroids				
Methylprednisolone	1251 (19.6%)	490 (19.1%)	-0.0140	-0.1184
Dexamethasone	334 (5.2%)	133 (5.2%)	-0.0029	-0.0077
Immunomodulator				
Interferon-alpha	2242 (35.2%)	857 (33.4%)	-0.0383	-0.1823

Abbreviations: QPT, Qingfei Paidu Tang; IPTW, inverse probability of treatment weighting; SMD, standardized mean difference; IQR, inter-quartile range; HR, heart rate; RR, respiratory rate; COPD: chronic obstructive pulmonary disease

480

Table 2. Associations between Qingfei Paidu Tang use and mortality in the crude

analysis, multivariable analysis, and propensity-score analyses

Analysis	Mortality	
No. of events/no. of patients at risk (%)		
Qingfei Paidu Tang	30 (1.2)	
No Qingfei Paidu Tang	304(4.8)	
Crude analysis-hazard ratio (95% CI)	0.17(0.11-0.26)	
Multivariable analysis- hazard ratio (95% CI)	0.23(0.15-0.36)	
Propensity-score analysis- hazard ratio (95%		
CI)		
With inverse probability weighting	0.50(0.37-0.66)	
With matching	0.42(0.24-0.74)	
Adjusted as a covariant	0.24(0.15-0.37)	

Abbreviations: 95% CI, 95% confidence interval

FIGURE LEGENDS Figure 1. Flowchart of the study cohort COVID-19, coronavirus disease 2019; QPT, Qingfei Paidu Tang Figure 2. Kaplan-Meier survival curves for in-hospital mortality in inverse 492 493 probability treatment weighting analysis 494 QPT, Qingfei Paidu Tang Figure 3. Hazard ratios of in-hospital mortality across subgroups in inverse 495 496 probability treatment weighting analysis HR, hazard ratio; 95% CI, 95% confidence interval.

489

490

491

497





